利伐沙班在西班牙非瓣膜性心房颤动患者中预防卒中的应用。
Use of rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain.
作者信息
Martí Edelmira, Segado Alejandra, Pastor-Galán Irene, Amat Paula, Remigia Maria José, Solano Carlos, Navarro Blanca
机构信息
Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario, Valencia, Spain.
Department of Medicine, School of Medicine, University of Valencia, Valencia, Spain.
出版信息
Future Cardiol. 2018 May;14(3s):3-8. doi: 10.2217/fca-2018-0020.
AIM
To analyze the clinical profile and rates of stroke, major bleeding and intracranial hemorrhage of patients with atrial fibrillation (AF) treated with rivaroxaban in clinical practice.
METHODS
Retrospective study of AF patients anticoagulated with rivaroxaban in a Healthcare Area of Valencia, Spain. Patients started treatment with rivaroxaban from July 2012 to December 2015.
RESULTS
A total of 230 patients (mean age 76.9 ± 9.9 years; CHADS-VASc 4.3 ± 1.7; HAS-BLED 1.7 ± 0.9) were included. Rates of stroke, major bleeding and intracranial bleeding were 0.4, 1.9 and 0.5 events per 100 patient-years, respectively.
CONCLUSION
In this cohort of AF patients anticoagulated with rivaroxaban, despite patients being older and having a high thromboembolic risk, rates of stroke, major bleeding and intracranial bleeding were low.
目的
分析在临床实践中接受利伐沙班治疗的心房颤动（AF）患者的临床特征、中风发生率、严重出血和颅内出血发生率。
方法
对西班牙巴伦西亚一个医疗区域内接受利伐沙班抗凝治疗的AF患者进行回顾性研究。患者于2012年7月至2015年12月开始使用利伐沙班治疗。
结果
共纳入230例患者（平均年龄76.9±9.9岁；CHADS-VASc评分4.3±1.7；HAS-BLED评分1.7±0.9）。中风、严重出血和颅内出血的发生率分别为每100患者年0.4、1.9和0.5次事件。
结论
在这个接受利伐沙班抗凝治疗的AF患者队列中，尽管患者年龄较大且血栓栓塞风险较高，但中风、严重出血和颅内出血的发生率较低。
Zotero 插件